Orgenesis Inc. (ORGS): Price and Financial Metrics

Orgenesis Inc. (ORGS): $0.49

0.07 (-11.92%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

Add ORGS to Watchlist
Sign Up

ORGS Price/Volume Stats

Current price $0.49 52-week high $1.50
Prev. close $0.56 52-week low $0.25
Day low $0.49 Volume 76,100
Day high $0.59 Avg. volume 236,958
50-day MA $0.61 Dividend yield N/A
200-day MA $0.69 Market Cap 15.72M

ORGS Stock Price Chart Interactive Chart >


Orgenesis Inc. (ORGS) Company Bio


Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.


ORGS Latest News Stream


Event/Time News Detail
Loading, please wait...

ORGS Latest Social Stream


Loading social stream, please wait...

View Full ORGS Social Stream

Latest ORGS News From Around the Web

Below are the latest news stories about ORGENESIS INC that investors may wish to consider to help them evaluate ORGS as an investment opportunity.

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

Orgenesis Inc. ( NASDAQ:ORGS ) is possibly approaching a major achievement in its business, so we would like to shine...

Yahoo | November 22, 2023

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM

GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it ranked 171 on the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Vered Caplan, CEO of Orgenesis, commented, “We are very proud

Yahoo | November 14, 2023

Orgenesis Provides Business Update for the Third Quarter of 2023

Advances rollout of POCare Platform and POCare TherapiesGERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the third quarter ended September 30, 2023. Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercial launch of our POCare Platform through Octomera, building out a decentralized

Yahoo | November 13, 2023

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering

GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.1 million of its common stock and warrants to purchase common stock in a registered direct offering. The combined effective purchase price for each share of common stoc

Yahoo | November 8, 2023

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

GERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced continued progression of the Point of Care (POCare) network and infrastructure for the advanced therapeutic services and facilities business through its subsidiary Octomera. The teams have been confirmed as an industrial partner to the University of California Davis, a lead

Yahoo | November 2, 2023

Read More 'ORGS' Stories Here

ORGS Price Returns

1-mo -37.91%
3-mo N/A
6-mo -44.94%
1-year -57.39%
3-year -90.58%
5-year -89.88%
YTD -2.14%
2023 -74.32%
2022 -32.29%
2021 -36.00%
2020 -3.43%
2019 -0.43%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!